Anti-Atherosclerotic Action of a New Stimulator of Soluble Guanylate Cyclase in an Experiment

• Published in: Bulletin of experimental biology and medicine 2023, Vol.174 (3), p.333-336
• Main Authors: Bykov, V. V., Bykova, A. V., Dzyuman, A. N., Ivanov, V. V., Khazanov, V. A., Vengerovskii, A. I., Udut, V. V.
• Format: Article
• Language: English
• Subjects: Animals; Aorta; Arteriosclerosis; Atherosclerosis; Atherosclerosis - drug therapy; Biological products; Biomedical and Life Sciences; Biomedicine; Blood vessels; Cell Biology; Cholesterol; Cholesterol, LDL; Coronary vessels; Development and progression; Dyslipidemia; Dyslipidemias - drug therapy; Endothelium; Guanylate Cyclase; Hypolipidemic activity; Internal Medicine; Laboratory Medicine; Lipoprotein lipase; Low density lipoprotein; Low density lipoproteins; Metabolic disorders; Mice; Mice, Inbred C57BL; Oral administration; Pathology; Soluble Guanylyl Cyclase; Triglycerides; Xanthoma; Xanthomatosis
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-023-05703-7

We studied the effect of an indolinone derivative GRS on the development of experimental atherosclerosis in C57BL/6 mice. Atherosclerosis was modeled by intraperitoneal administration of endothelial lipoprotein lipase inhibitor Kolliphor P 407 micro Geismar over 5 months. GRS was administered orally in a dose of 10 mg/kg once a day throughout the experiment. In 5 months, the levels of total cholesterol, LDL, and triglycerides in blood serum, as well as histological composition of the ascending aorta were studied. In mice with experimental atherosclerosis, we observed pronounced dyslipidemia with an increase in serum cholesterol, LDL, and triglycerides and accumulation of xanthoma cells in the aorta wall. Repeat administration of GRS did not eliminate dyslipidemia, but prevented an increase in the number of xanthoma cells in the aorta wall ( p